-
1
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
DOI 10.1056/NEJMoa0706482
-
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15. (Pubitemid 350106708)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.20
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
Montalescot, G.4
Ruzyllo, W.5
Gottlieb, S.6
Neumann, F.-J.7
Ardissino, D.8
De Servi, S.9
Murphy, S.A.10
Riesmeyer, J.11
Weerakkody, G.12
Gibson, C.M.13
Antman, E.M.14
-
2
-
-
69949122850
-
Prasugrel in clinical practice
-
Bhatt DL. Prasugrel in clinical practice. N Engl J Med. 2009;361:940-2.
-
(2009)
N Engl J Med
, vol.361
, pp. 940-942
-
-
Bhatt, D.L.1
-
3
-
-
34447547659
-
Developments in post-marketing comparative effectiveness research
-
DOI 10.1038/sj.clpt.6100249, PII 6100249
-
Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82:143-56. (Pubitemid 47075343)
-
(2007)
Clinical Pharmacology and Therapeutics
, vol.82
, Issue.2
, pp. 143-156
-
-
Schneeweiss, S.1
-
4
-
-
33748680917
-
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
-
DOI 10.1016/j.ahj.2006.04.012, PII S0002870306003486
-
Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-35. (Pubitemid 44396884)
-
(2006)
American Heart Journal
, vol.152
, Issue.4
, pp. 627-635
-
-
Wiviott, S.D.1
Antman, E.M.2
Gibson, C.M.3
Montalescot, G.4
Riesmeyer, J.5
Weerakkody, G.6
Winters, K.J.7
Warmke, J.W.8
McCabe, C.H.9
Braunwald, E.10
-
5
-
-
81355139590
-
Assessing the comparative effectiveness of newly marketed medications: Methodological challenges and implications for drug development
-
Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011;90:777-90.
-
(2011)
Clin Pharmacol Ther
, vol.90
, pp. 777-790
-
-
Schneeweiss, S.1
Gagne, J.J.2
Glynn, R.J.3
Ruhl, M.4
Rassen, J.A.5
-
6
-
-
78149345321
-
Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices
-
Resnic FS, Gross TP, Marinac-Dabic D, et al. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA. 2010;304:2019-27.
-
(2010)
JAMA
, vol.304
, pp. 2019-2027
-
-
Resnic, F.S.1
Gross, T.P.2
Marinac-Dabic, D.3
-
7
-
-
84859852184
-
Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples
-
Wahl PM, Gagne JJ, Wasser TE, et al. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf. 2012;35:407-16.
-
(2012)
Drug Saf
, vol.35
, pp. 407-416
-
-
Wahl, P.M.1
Gagne, J.J.2
Wasser, T.E.3
-
8
-
-
84862626391
-
Active safety monitoring of newly marketed medications in a distributed data network: Application of a semi-automated monitoring system
-
Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012;92:80-6.
-
(2012)
Clin Pharmacol Ther
, vol.92
, pp. 80-86
-
-
Gagne, J.J.1
Glynn, R.J.2
Rassen, J.A.3
-
9
-
-
84857042212
-
Active safety monitoring of new medical products using electronic healthcare data: Selecting alerting rules
-
Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23:238-46.
-
(2012)
Epidemiology
, vol.23
, pp. 238-246
-
-
Gagne, J.J.1
Rassen, J.A.2
Walker, A.M.3
Glynn, R.J.4
Schneeweiss, S.5
-
10
-
-
0142157169
-
Evaluating Medication Effects Outside of Clinical Trials: New-User Designs
-
DOI 10.1093/aje/kwg231
-
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20. (Pubitemid 37323253)
-
(2003)
American Journal of Epidemiology
, vol.158
, Issue.9
, pp. 915-920
-
-
Ray, W.A.1
-
11
-
-
77956625112
-
A basic study design for expedited safety signal evaluation based on electronic healthcare data
-
Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858-68.
-
(2010)
Pharmacoepidemiol Drug Saf
, vol.19
, pp. 858-868
-
-
Schneeweiss, S.1
-
12
-
-
77953517347
-
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population
-
Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19:596-603.
-
(2010)
Pharmacoepidemiol Drug Saf
, vol.19
, pp. 596-603
-
-
Wahl, P.M.1
Rodgers, K.2
Schneeweiss, S.3
-
13
-
-
0036792795
-
Validating administrative data in stroke research
-
Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465-70.
-
(2002)
Stroke
, vol.33
, pp. 2465-2470
-
-
Tirschwell, D.L.1
Longstreth Jr., W.T.2
-
14
-
-
0035500992
-
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data
-
DOI 10.1093/aje/154.9.854
-
Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-64. (Pubitemid 33000813)
-
(2001)
American Journal of Epidemiology
, vol.154
, Issue.9
, pp. 854-864
-
-
Schneeweiss, S.1
Seeger, J.D.2
Maclure, M.3
Wang, P.S.4
Avorn, J.5
Glynn, R.J.6
-
15
-
-
79956217851
-
A combined comorbidity score predicted mortality in elderly patients better than existing scores
-
Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64:749-59.
-
(2011)
J Clin Epidemiol
, vol.64
, pp. 749-759
-
-
Gagne, J.J.1
Glynn, R.J.2
Avorn, J.3
Levin, R.4
Schneeweiss, S.5
-
16
-
-
77951622706
-
The central role of the propensity score in observational studies for causal effects
-
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
-
(1983)
Biometrika
, vol.70
, pp. 41-55
-
-
Rosenbaum, P.R.1
Rubin, D.B.2
-
17
-
-
67651042983
-
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data
-
Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512-22.
-
(2009)
Epidemiology
, vol.20
, pp. 512-522
-
-
Schneeweiss, S.1
Rassen, J.A.2
Glynn, R.J.3
Avorn, J.4
Mogun, H.5
Brookhart, M.A.6
-
18
-
-
84856034091
-
Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system
-
Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):41-9.
-
(2012)
Pharmacoepidemiol Drug Saf
, vol.21
, Issue.SUPPL. 1
, pp. 41-49
-
-
Rassen, J.A.1
Schneeweiss, S.2
-
19
-
-
84879890519
-
Confounding adjustment in comparative effectiveness research conducted within distributed research networks
-
Toh S, Gagne JJ, Rassen JA, Fireman BH, Kulldorff M, Brown JS. Confounding adjustment in comparative effectiveness research conducted within distributed research networks. Med Care. 2013;51:S4-10.
-
(2013)
Med Care
, vol.51
-
-
Toh, S.1
Gagne, J.J.2
Rassen, J.A.3
Fireman, B.H.4
Kulldorff, M.5
Brown, J.S.6
-
20
-
-
79958845225
-
Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples
-
Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011;173:1404-13.
-
(2011)
Am J Epidemiol
, vol.173
, pp. 1404-1413
-
-
Rassen, J.A.1
Glynn, R.J.2
Brookhart, M.A.3
Schneeweiss, S.4
-
21
-
-
84862230912
-
An event-based approach for comparing the performance of methods for prospective medical product monitoring
-
Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012;21:631-9.
-
(2012)
Pharmacoepidemiol Drug Saf
, vol.21
, pp. 631-639
-
-
Gagne, J.J.1
Walker, A.M.2
Glynn, R.J.3
Rassen, J.A.4
Schneeweiss, S.5
-
23
-
-
79955553942
-
Availability of comparative efficacy data at the time of drug approval in the United States
-
Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011;305:1786-9.
-
(2011)
JAMA
, vol.305
, pp. 1786-1789
-
-
Goldberg, N.H.1
Schneeweiss, S.2
Kowal, M.K.3
Gagne, J.J.4
-
24
-
-
84867177857
-
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
-
Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-309.
-
(2012)
N Engl J Med
, vol.367
, Issue.14
, pp. 1297-1309
-
-
Roe, M.T.1
Armstrong, P.W.2
Fox, K.A.3
-
25
-
-
84856050291
-
Design considerations in an active medical product safety monitoring system
-
Gagne JJ, Fireman B, Ryan PB, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):32-40.
-
(2012)
Pharmacoepidemiol Drug Saf
, vol.21
, Issue.SUPPL. 1
, pp. 32-40
-
-
Gagne, J.J.1
Fireman, B.2
Ryan, P.B.3
-
26
-
-
82555196119
-
Full coverage for preventive medications after myocardial infarction
-
Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-97.
-
(2011)
N Engl J Med
, vol.365
, pp. 2088-2097
-
-
Choudhry, N.K.1
Avorn, J.2
Glynn, R.J.3
-
27
-
-
79551636787
-
Utility of electronic patient records in primary care for stroke secondary prevention trials
-
Dregan A, Toschke MA, Wolfe CD, Rudd A, Ashworth M, Gulliford MC. Utility of electronic patient records in primary care for stroke secondary prevention trials. BMC Public Health. 2011;11:86.
-
(2011)
BMC Public Health
, vol.11
, pp. 86
-
-
Dregan, A.1
Toschke, M.A.2
Wolfe, C.D.3
Rudd, A.4
Ashworth, M.5
Gulliford, M.C.6
-
28
-
-
84859004974
-
Pragmatic randomised trials using routine electronic health records: Putting them to the test
-
Staa TP, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55.
-
(2012)
BMJ
, vol.344
-
-
Staa, T.P.1
Goldacre, B.2
Gulliford, M.3
-
29
-
-
84881502708
-
You can observe a lot (about medical products) by watching (those who use them)
-
Gagne JJ. You can observe a lot (about medical products) by watching (those who use them). Epidemiology. 2013;24:700-2.
-
(2013)
Epidemiology
, vol.24
, pp. 700-702
-
-
Gagne, J.J.1
-
30
-
-
84884290134
-
Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research
-
Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013;16:1054-62.
-
(2013)
Value Health
, vol.16
, pp. 1054-1062
-
-
Gagne, J.J.1
Bykov, K.2
Willke, R.J.3
Kahler, K.H.4
Subedi, P.5
Schneeweiss, S.6
-
31
-
-
79851472033
-
Developing the sentinel system - A national resource for evidence development
-
Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the sentinel system-a national resource for evidence development. N Engl J Med. 2011;364:498-9.
-
(2011)
N Engl J Med
, vol.364
, pp. 498-499
-
-
Behrman, R.E.1
Benner, J.S.2
Brown, J.S.3
McClellan, M.4
Woodcock, J.5
Platt, R.6
-
32
-
-
84862932391
-
The U.S. Food and Drug Administration's Mini-Sentinel program: Status and direction
-
Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):1-8.
-
(2012)
Pharmacoepidemiol Drug Saf
, vol.21
, Issue.SUPPL. 1
, pp. 1-8
-
-
Platt, R.1
Carnahan, R.M.2
Brown, J.S.3
|